Rapid Wuchereria bancrofti-specific antigen Wb123-based IgG4 immunoassays as tools for surveillance following mass drug administration programs on lymphatic filariasis

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1155-1161

  Steel, Cathy ^a   Golden, Allison ^b   Kubofcik, Joseph ^a   LaRue, Nicole ^b   De los Santos, Tala ^b   Domingo, Gonzalo J ^b   Nutman, Thomas B ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE P1; IMMUNOGLOBULIN G4; PARASITE ANTIGEN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WB123 ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; BRUGIA MALAYI; DISEASE TRANSMISSION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSED SEQUENCE TAG; HELMINTHIASIS; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; LYMPHATIC FILARIASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SENSITIVITY AND SPECIFICITY; WORLD HEALTH ORGANIZATION; WUCHERERIA BANCROFTI;

ANIMALS; ANTHELMINTICS; ANTIBODIES, HELMINTH; ANTIGENS, HELMINTH; CLINICAL LABORATORY TECHNIQUES; DRUG MONITORING; ELEPHANTIASIS, FILARIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOCHROMATOGRAPHY; IMMUNOGLOBULIN G; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; WUCHERERIA BANCROFTI;

EID: 84880910788     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00252-13     Document Type: Article

References (17)

1. World Health Organization. 2012. Global programme to eliminate lymphatic filariasis: progress report, 2011. Weekly epidemiological record, no. 37, 87, 346-356. World Health Organization, Geneva, Switzerland http://www.who.int/wer/ 2012/wer8737.pdf.
2. World Health Organization. 2011. Global programme to eliminate lymphatic filariasis: monitoring and epidemiological assessment of mass drug administration. World Health Organization, Geneva, Switzerland.
3. Moss DM, Priest JW, Boyd A, Weinkopff T, Kucerova Z, Beach MJ, Lammie PJ. 2011. Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis. Am. J. Trop. Med. Hyg. 85:229-237.
4. Ramzy RM, El Setouhy M, Helmy H, Ahmed ES, Abd Elaziz KM, Farid HA, Shannon WD, Weil GJ. 2006. Effect of yearly mass drug administration with diethylcarbamazine and albendazole on bancroftian filariasis in Egypt: a comprehensive assessment. Lancet 367:992-999.
5. Abdul Rahman R, Hwen-Yee C, Noordin R. 2007. Pan LF-ELISA using BmR1 and BmSXP recombinant antigens for detection of lymphatic filariasis. Filaria J. 6:10. doi:10.1186/1475-2883-6-10.
6. Pandiaraja P, Arunkumar C, Hoti SL, Rao DN, Kaliraj P. 2010. Evaluation of synthetic peptides of WbSXP-1 for the diagnosis of human lymphatic filariasis. Diagn. Microbiol. Infect. Dis. 68:410-415.
7. Krushna NS, Shiny C, Dharanya S, Sindhu A, Aishwarya S, Narayanan RB. 2009. Immunolocalization and serum antibody responses to Brugia malayi pepsin inhibitor homolog (Bm-33). Microbiol. Immunol. 53:173-183.
8. Weil GJ, Curtis KC, Fischer PU, Won KY, Lammie PJ, Joseph H, Melrose WD, Brattig NW. 2010. A multicenter evaluation of a new antibody test kit for lymphatic filariasis employing recombinant Brugia malayi antigen Bm-14. Acta Trop. 120:S19 -S22.
9. Helmy H, Weil GJ, Ellethy AS, Ahmed ES, Setouhy ME, Ramzy RM. 2006. Bancroftian filariasis: effect of repeated treatment with diethylcarbamazine and albendazole on microfilaraemia, antigenaemia and antifilarial antibodies. Trans. R. Soc. Trop. Med. Hyg. 100:656-662.
10. Lammie PJ, Weil G, Noordin R, Kaliraj P, Steel C, Goodman D, Lakshmikanthan VB, Ottesen E. 2004. Recombinant antigen-based antibody assays for the diagnosis and surveillance of lymphatic filariasis-A multicenter trial. Filaria J. 3:9. doi:10.1186/1475-2883-3-9.
11. Weil GJ, Kastens W, Susapu M, Laney SJ, Williams SA, King CL, Kazura JW, Bockarie MJ. 2008. The impact of repeated rounds of mass drug administration with diethylcarbamazine plus albendazole on bancroftian filariasis in Papua New Guinea. PLoS Negl. Trop. Dis. 2:e344. doi:10.1371/journal.pntd.0000344.
12. Hamlin KL, Moss DM, Priest JW, Roberts J, Kubofcik J, Gass K, Streit TG, Nutman TB, Eberhard ML, Lammie PJ. 2012. Longitudinal moni-toring of the development of antifilarial antibodies and acquisition of Wuchereria bancrofti in a highly endemic area of Haiti. PLoS Negl. Trop. Dis. 6:e1941. doi:10.1371/journal.pntd.0001941.
13. Kubofcik J, Fink DL, Nutman TB. 2012. Identification of Wb123 as an early and specific marker of Wuchereria bancrofti infection. PLoS Negl. Trop. Dis. 6:e1930. doi:10.1371/journal.pntd.0001930.
14. Steel C, Kubofcik J, Ottesen EA, Nutman TB. 2012. Antibody to the filarial antigen Wb123 reflects reduced transmission and decreased exposure in children born following single mass drug administration (MDA). PLoS Negl. Trop. Dis. 6:e1940. doi:10.1371/journal.pntd.0001940.
15. Fouda GG, Leke RF, Long C, Druilhe P, Zhou A, Taylor DW, Johnson AH. 2006. Multiplex assay for simultaneous measurement of antibodies to multiple Plasmodium falciparum antigens. Clin. Vaccine Immunol. 13: 1307-1313.
16. Lal RB, Ottesen EA. 1988. Enhanced diagnostic specificity in human filariasis by IgG4 antibody assessment. J. Infect. Dis. 158:1034-1037.
17. Steel C, Ottesen EA, Weller PF, Nutman TB. 2001. Worm burden and host responsiveness in Wuchereria bancrofti infection: use of antigen detection to refine linear assessments from the South Pacific. Am. J. Trop. Med. Hyg. 65:498-503.